Abstract 2280
Background
We compared the prognosis of patients with breast cancer according to surgical options including mastectomy with reconstruction after neoadjuvant chemotherapy (NAC). We also assessed the association between prognosis and surgical options according to clinical stage and clinical response in patients with neoadjuvant chemotherapy.
Methods
A total of 140,712 patients were enrolled in the Korean Breast Cancer Society Registry database between 2000 and 2014 in Korea. We compared the prognosis of three groups; 1) patients who underwent breast-conserving surgery (BCS), 2) patients who underwent mastectomy, and 3) patients who underwent mastectomy with reconstruction.
Results
Of all 6,634 patients who were treated with NAC, 1,745 patients underwent BCS, 1,459 patients underwent mastectomy, and 363 patients underwent mastectomy with reconstruction. In survival analysis, five-year survival rate (5YSR) of mastectomy with BR group was not inferior compare to other groups in clinical stage IIA and IIB. 5YSR of mastectomy with BR group was 100% and 90.0% clinical stage IIA and IIB, whereas 5YSR of mastectomy group was 97.2% and 86.2% (clinical stage IIA and IIB; P = 0.033 and 0.023). In clinical stage IIIA and IIIB, there was no significant difference in 5YSR between mastectomy with BR group and other groups. However, women who underwent mastectomy with BR had a worse prognosis compare to BCS or mastectomy group in clinical stage IIIC. In univariate analysis by Cox regression method according to surgical methods, women who underwent mastectomy with BR had a worse prognosis compared to other groups in patients with clinical stage IIIC (HR 5.88; 95% CI 2.17-15.89; P < 0.001). In multivariate analysis, women who underwent mastectomy with reconstruction followed by NAC were associated with a worse prognosis in clinical stage IIIC. (HR 3.41; 95% CI 1.29-8.99; P = 0.013).
Conclusions
In this study, women who underwent mastectomy with reconstruction followed by NAC were associated with a worse prognosis in the clinically advanced stage. This study suggests that reconstruction followed by NAC should be considered for appropriately selected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract